PRVL News
Archived Headlines
- June is getting a flood of biotech IPOs with these 9 deals on the calendar 06/18/19
- US IPO Week Ahead: A biotech wave drives 7 IPOs while Slack targets a direct listing 06/14/19
- Parkinson's biotech Prevail Therapeutics sets terms for $125 million IPO 06/10/19
- Gene therapy biotech Prevail Therapeutics files for a $100 million IPO 05/24/19
June's flood of biotech IPOs continues with these 4 deals
June is seeing a wave of biotech IPOs. Five priced last week, and four more are on ...read more
US IPO Weekly Recap: WORK's direct listing works as Slack and 6 others go public
Slack's (WORK) widely-covered direct listing was hailed as a success. Slack opened on Thursday at $38.50, well above the NYSE's "reference price" of $26, and more than triple its last round less than a year ago. And yet, new public...read more
Parkinson's biotech Prevail Therapeutics prices IPO at $17 midpoint
Prevail Therapeutics, an early stage biotech developing gene therapies for neurodegenerative diseases, raised $125 million by offering 7.4 million shares at $17, the midpoint of the $16 to $18 range. Prevail Therapeutics plans to list on the Nasdaq under the...read more
Prevail IPO Aims to Conquer Parkinson’s
Formed by OrbiMed, the Silverstein Foundation for Parkinson's with GBA, and a Columbia University neurologist, Prevail (PRVL) is applying gene therapies to genetic subsets of neurodegenerative diseases, including Parkinson's Disease (PD). It’s using...read more